N4 Pharma Nuvec technology could be used for multiple vaccines not just Covid-19 (Interview)

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss its Covid-19 proof of concept work utilising Nuvec® loaded with Coronavirus plasmid. Nigel provides us with a snapshot of the company, the background to this Covid-19 Proof of Concept update, moving into in vivo studies and what investors should expect in terms of newsflow over the coming weeks and months.

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

The company’s business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4P will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    DirectorsTalk

    More articles like this

    DirectorsTalk

    With the focus on drug delivery can N4 Pharma fill a need in the market?

    N4 Pharma plc (LON:N4P) are a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs

    DirectorsTalk

    N4 Pharma raises £2 million through placing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £2 million (before expenses) through a placing of 25,000,000 new ordinary shares of

    DirectorsTalk

    N4 Pharma update on Nanomerics research collaboration

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided the following update on its ongoing research collaboration agreement with Nanomerics Limited. As announced on 11 February

    DirectorsTalk

    N4 Pharma Q&A: Confirming Nuvec’s versatility (LON:N4P)

    N4 Pharma’s Nigel Theobald discusses their latest operational update, the importance of demonstrating formulation, key milestones for the COVID-19 proof of concept programme, whyan orally administered vaccine has greater challenges than a subcutaneous injection and what news flow investors can expect from the company for the rest of the year in this exclusive interview with DirectorsTalk.

    DirectorsTalk

    N4 Pharma make significant strides with optimisation work

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided the following update on its ongoing work programmes. Optimisation The optimisation programme is investigating different formulations of Nuvec®